196 related articles for article (PubMed ID: 23266054)
1. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
2. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
3. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Zhang HL; Zhu Y; Qin XJ; Wang CF; Yao XD; Zhang SL; Dai B; Zhu YP; Shi GH; Ye DW
Clin Genitourin Cancer; 2013 Jun; 11(2):134-40. PubMed ID: 23058498
[TBL] [Abstract][Full Text] [Related]
4. Third-line dovitinib in metastatic renal cell carcinoma.
Schmidinger M
Lancet Oncol; 2014 Mar; 15(3):245-6. PubMed ID: 24556039
[No Abstract] [Full Text] [Related]
5. Effects of antiangiogenic therapy.
von Falck C; Wacker F; Rosenthal H
J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
[No Abstract] [Full Text] [Related]
6. Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Ishihara H; Kondo T; Tanabe K
Ther Apher Dial; 2017 Aug; 21(4):414-416. PubMed ID: 28593648
[No Abstract] [Full Text] [Related]
7. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
8. [Drug now immediately available in Germany].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
[No Abstract] [Full Text] [Related]
9. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
10. New options for second-line therapy of advanced renal cancer.
Bex A
Lancet Oncol; 2013 May; 14(6):450-1. PubMed ID: 23598169
[No Abstract] [Full Text] [Related]
11. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib-induced pancreatitis.
Amar S; Wu KJ; Tan WW
Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
[No Abstract] [Full Text] [Related]
13. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
[TBL] [Abstract][Full Text] [Related]
14. Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Ouzaid I; Bensalah K
Eur Urol; 2015 Sep; 68(3):542-3. PubMed ID: 26001611
[No Abstract] [Full Text] [Related]
15. Urological cancer: second-line option for metastatic RCC.
Marchesi V
Nat Rev Clin Oncol; 2013 Jun; 10(6):305. PubMed ID: 23629471
[No Abstract] [Full Text] [Related]
16. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
17. Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
Yang L; Yu SY; Hu GY
Chin J Cancer; 2013 Jun; 32(6):353-6. PubMed ID: 23237217
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
Shah CH; Viktorsson K; Sherif A; Kanter L; Grybäck P; Lewensohn R; Sandström P; Nilsson S; Ullén A
Anticancer Drugs; 2013 Jul; 24(6):648-52. PubMed ID: 23542751
[TBL] [Abstract][Full Text] [Related]
19. Kidney cancer: targeting FGF for third-line treatment of mRCC.
Payton S
Nat Rev Urol; 2014 Apr; 11(4):186. PubMed ID: 24595120
[No Abstract] [Full Text] [Related]
20. Maturing of renal cancer therapeutics.
Stadler WM
J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
[No Abstract] [Full Text] [Related]
[Next] [New Search]